PPIDT00358
Drug Information
| Name | Enfortumab vedotin |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB13007 |
| Type | biotech |
| Indication | Enfortumab vedotin is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting.[L10836,L41995] Enfortumab vedotin can also be indicated in combination with pembrolizumab in adult patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing chemotherapy under accelerated approval from the FDA.[L45813] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Intravenous |
20 mg
|
| Injection, powder, for solution | Intravenous |
30 mg
|
| Powder, for solution | Intravenous |
20 mg / vial
|
| Powder, for solution | Intravenous |
30 mg / vial
|
| Solution | Intravenous |
20.00 mg
|
| Powder | — |
20 mg
|
| Powder | — |
30 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
20 mg/2mL
|
| Injection, powder, lyophilized, for solution | Intravenous |
30 mg/3mL
|
Target Information